spezielle fachgebiete
Fischöl
Literatur
1.Xue Z, Sharpe PL, Hong SP, et al: Production of omega-3 eicosapentaenoic acid by metabolic engineering ofYarrowia lipolytica.Nat Biotechnol31(8):734-740, 2013. doi: 10.1038/nbt.2622 2.MacLean CH, Mojica WA, Morton SC, et al: Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis.Evid Rep Technol Assess (Summ)2004;(89):1-4. 3.Kalstad AA, Myhre PL, Laake K, et al: Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction: a randomized, controlled trial.Circulation143(6):528-539, 2021. doi:10.1161/CIRCULATIONAHA.120.052209 4.Balk EM, Adams GP, Langberg V, et al: Omega-3 fatty acids and cardiovascular disease: an updated systematic review.Evid Rep Technol Assess (Full Rep)(223):1-1252, 2016. doi:10.23970/AHRQEPCERTA223 5.Abdelhamid AS, Brown TJ, Brainard JS, et al: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (review).Cochrane Database Syst Rev3:CD003177, 2020. doi: 10.1002/14651858.CD003177.pub5 6.Bhatt DL, Steg PG, Miller M, et al: Cardiovascular risk reduction withicosapent ethylfor hypertriglyceridemia.N Engl J Med380(1):11-22, 2019. doi: 10.1056/NEJMoa1812792 7.Skulas-Ray A, Wilson PWF, Harris WS, et al: Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association.Circulation140(12):e673-e691, 2019. doi: 10.1161/CIR.0000000000000709 8.Pryce R, Bernaitis N, Davey AK, et al: The use offish oilwithwarfarindoes not significantly affect either the International Normalized Ratio or incidence of adverse events in patients with atrial fibrillation and deep vein thrombosis: a retrospective study.Nutrients8(9):578, 2016. doi:10.3390/nu8090578 